Aavantibio was founded by pioneers in genetic research and experts in gene therapy development and commercializatoin. They are leveraging deep expertise in the science of innovative gene transfer and gene editing technologies to build a sustainable platform approach that starts with Friedreich's ataxia, or FA, a progressive genetic neuromuscular disease with high unmet medical need, with a vision to extend to a broader spectrum of genetic diseases. They are also building a scalable manufacturing process that will allow production of their gene therapy product candidates efficiently and with breakthrough yields. Their competitive pipeline focuses on utilizing AAV-mediated approaches, immunomodulation strategies, and dual routes of administration.